Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.

Cancer science - 1 Oct 2021

Tomida Akimasa, Yagyu Shigeki, Nakamura Kayoko, Kubo Hiroshi, Yamashima Kumiko, Nakazawa Yozo, Hosoi Hajime, Iehara Tomoko

Abstract excerpt

Disialoganglioside (GD2)-specific chimeric antigen receptor (CAR)-T cells (GD2-CAR-T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma. However, the effectiveness of immunotherapy using these cells is limited, and requires improvement. Combined therapy with CAR-T cells and molecular targeted drugs could be a promising strategy to enhance the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coumarins
Share to Gangliosides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Mitogen-Activated Protein Kinase Kinases

Share to Neuroblastoma

Share to Pyridones

Share to Pyrimidinones

Share to Receptors, Chimeric Antigen

Source

Open in PubMed Open full text

Identifiers

PMID: 34382720
DOI: 10.1111/cas.15074
PMCID: PMC8486218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.PMID 34382720Read ↗

GD2 targeting CAR T cells for neuroblastomaSemantic proximity Read ↗

An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersSemantic proximity Read ↗

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

Biological Insight and Recent Advancement in the Treatment of NeuroblastomaSemantic proximity Read ↗

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cellsSemantic proximity Read ↗

Systematic Targeting of GD2‐Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector PlatformSemantic proximity Read ↗

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in <i>TH-MYCN</i> miceSemantic proximity Read ↗

GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric PatientsSemantic proximity Read ↗

State of the Art in Immunotherapy of NeuroblastomaSemantic proximity Read ↗

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with NeuroblastomaSemantic proximity Read ↗

High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma ModelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.